{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:49:18Z","timestamp":1787021358293,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multicenter randomized controlled trials (RCTs) in esophagogastric cancer surgery have repeatedly failed to demonstrate overall survival (OS) benefits for technical interventions. This raises concerns about trial design frameworks, particularly surgical quality assurance (SQA) and their impact on statistical power and sample size requirements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review of MEDLINE, Embase, and Cochrane CENTRAL (January 1990 to June 2024) to identify multicenter RCTs evaluating curative surgical interventions for esophageal or gastric cancer that reported OS outcomes with \u2265 12\u00a0months of follow-up. Trials were assessed for SQA strategies, protocol adherence, and sample size assumptions. Post hoc power analyses and statistical simulations modeled the impact of surgical variability on trial outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 27 eligible RCTs; 10 were powered for OS superiority, but none showed significant OS benefit. Suboptimal SQA was common, including limited surgeon credentialing, poor adherence monitoring, and inadequate technical standardization. Three trials were underpowered at design, and three failed to meet recruitment targets. Simulations showed that a technical nonadherence rate of 10% per arm could halve statistical power. Sample size requirements to preserve 80% power increased markedly, sometimes by thousands of participants. Most trials lacked internal piloting to assess protocol feasibility and baseline adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Inadequate SQA and failure to account for surgical variability may partly explain the lack of OS benefit in multicenter surgical RCTs. Embedding SQA and internal pilot studies into trial design may improve feasibility, ensure protocol fidelity, and strengthen the validity of future trials in complex oncologic surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18532-x","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:19:37Z","timestamp":1761239977000},"page":"1007-1015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reevaluating the Design of Multicenter Surgical Trials for Esophagogastric Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Bibek","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja T.","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George B.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"18532_CR1","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2024;74(3): 229-263. https:\/\/doi.org\/10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"issue":"1","key":"18532_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320. https:\/\/doi.org\/10.1056\/nejmoa055531.","journal-title":"N Engl J Med."},{"issue":"18","key":"18532_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/jco.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39(18):1995\u20132004. https:\/\/doi.org\/10.1200\/jco.20.03614.","journal-title":"J Clin Oncol."},{"issue":"10184","key":"18532_CR4","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/s0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2018","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet (Lond, Engl). 2018;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/s0140-6736(18)32557-1.","journal-title":"Lancet (Lond, Engl)."},{"issue":"1","key":"18532_CR5","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/s1470-2045(14)70419-x","volume":"16","author":"SR Markar","year":"2015","unstructured":"Markar SR, Wiggins T, Ni M, et al. Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic review. Lancet Oncol. 2015;16(1):e23\u201331. https:\/\/doi.org\/10.1016\/s1470-2045(14)70419-x.","journal-title":"Lancet Oncol."},{"key":"18532_CR6","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj. 2009;339:b2700\u2013b2700. https:\/\/doi.org\/10.1136\/bmj.b2700.","journal-title":"Bmj."},{"issue":"4","key":"18532_CR7","first-page":"1121","volume":"11","author":"A Delgado","year":"2021","unstructured":"Delgado A, Guddati AK. Clinical endpoints in oncology\u2014a primer. Am J cancer Res. 2021;11(4):1121\u201331.","journal-title":"Am J cancer Res."},{"key":"18532_CR8","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ."},{"issue":"2","key":"18532_CR9","first-page":"49","volume":"33","author":"I Farrance","year":"2012","unstructured":"Farrance I, Frenkel R. Uncertainty of measurement: a review of the rules for calculating uncertainty components through functional relationships. Clin Biochem Rev. 2012;33(2):49\u201375.","journal-title":"Clin Biochem Rev."},{"issue":"24","key":"18532_CR10","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MKB Parmar","year":"1998","unstructured":"Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815\u201334.","journal-title":"Stat Med."},{"issue":"1","key":"18532_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16. https:\/\/doi.org\/10.1186\/1745-6215-8-16.","journal-title":"Trials."},{"issue":"3","key":"18532_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2307\/2531201","volume":"42","author":"JM Lachin","year":"1986","unstructured":"Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42(3):507\u201319.","journal-title":"Biometrics."},{"issue":"1","key":"18532_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10120-011-0058-9","volume":"15","author":"J Fujita","year":"2012","unstructured":"Fujita J, Kurokawa Y, Sugimoto T, et al. Survival benefit of bursectomy in patients with resectable gastric cancer: interim analysis results of a randomized controlled trial. Gastric Cancer. 2012;15(1):42\u20138. https:\/\/doi.org\/10.1007\/s10120-011-0058-9.","journal-title":"Gastric Cancer."},{"issue":"6","key":"18532_CR14","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.surg.2014.12.024","volume":"157","author":"M Hirao","year":"2015","unstructured":"Hirao M, Kurokawa Y, Fujita J, et al. Long-term outcomes after prophylactic bursectomy in patients with resectable gastric cancer: Final analysis of a multicenter randomized controlled trial. Surgery. 2015;157(6):1099\u2013105. https:\/\/doi.org\/10.1016\/j.surg.2014.12.024.","journal-title":"Surgery."},{"issue":"4","key":"18532_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/bjs.9764","volume":"102","author":"Y Kurokawa","year":"2015","unstructured":"Kurokawa Y, Sasako M, Sano T, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. J Br Surg. 2015;102(4):341\u20138.","journal-title":"J Br Surg."},{"issue":"8","key":"18532_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/s1470-2045(06)70766-5","volume":"7","author":"M Sasako","year":"2006","unstructured":"Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644\u201351. https:\/\/doi.org\/10.1016\/s1470-2045(06)70766-5.","journal-title":"Lancet Oncol."},{"key":"18532_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2021.03.031","volume":"150","author":"M Degiuli","year":"2021","unstructured":"Degiuli M, Reddavid R, Tomatis M, et al. D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial. Eur J Cancer. 2021;150:10\u201322. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.031.","journal-title":"Eur J Cancer."},{"issue":"2","key":"18532_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/00000658-198902000-00005","volume":"209","author":"JL Gouzi","year":"1989","unstructured":"Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. Ann Surg. 1989;209(2):162\u20136. https:\/\/doi.org\/10.1097\/00000658-198902000-00005.","journal-title":"Ann Surg."},{"issue":"2","key":"18532_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000172225","volume":"11","author":"JL Gouzi","year":"1994","unstructured":"Gouzi JL, Bloom E, Labb\u00e9 F. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. Dig Surg. 1994;11(2):58\u201363. https:\/\/doi.org\/10.1159\/000172225.","journal-title":"Dig Surg."},{"issue":"2","key":"18532_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1200\/jco.1994.12.2.417","volume":"12","author":"AM Bunt","year":"1994","unstructured":"Bunt AM, Hermans J, Boon MC, et al. Evaluation of the extent of lymphadenectomy in a randomized trial of Western-versus Japanese-type surgery in gastric cancer. J Clin Oncol\u202f: Off J Am Soc Clin Oncol. 1994;12(2):417\u201322. https:\/\/doi.org\/10.1200\/jco.1994.12.2.417.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol."},{"issue":"7","key":"18532_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/s2468-1253(18)30090-6","volume":"3","author":"Y Kurokawa","year":"2018","unstructured":"Kurokawa Y, Doki Y, Mizusawa J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2018;3(7):460\u20138. https:\/\/doi.org\/10.1016\/s2468-1253(18)30090-6.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"18532_CR22","doi-asserted-by":"publisher","unstructured":"Lu J, Xu B bin, Zheng HL, et al. Robotic versus laparoscopic distal gastrectomy for resectable gastric cancer: a randomized phase 2 trial. Nat Commun. 2024;15(1):4668. https:\/\/doi.org\/10.1038\/s41467-024-49013-6","DOI":"10.1038\/s41467-024-49013-6"},{"issue":"12","key":"18532_CR23","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/nejm199903253401202","volume":"340","author":"JJ Bonenkamp","year":"1999","unstructured":"Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908\u201314. https:\/\/doi.org\/10.1056\/nejm199903253401202.","journal-title":"N Engl J Med."},{"issue":"11","key":"18532_CR24","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1200\/jco.2004.08.026","volume":"22","author":"HH Hartgrink","year":"2004","unstructured":"Hartgrink HH, van de Velde CJH, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol. 2004;22(11):2069\u201377. https:\/\/doi.org\/10.1200\/jco.2004.08.026.","journal-title":"J Clin Oncol."},{"issue":"5","key":"18532_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/s1470-2045(10)70070-x","volume":"11","author":"I Songun","year":"2010","unstructured":"Songun I, Putter H, Kranenbarg EMK, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439\u201349. https:\/\/doi.org\/10.1016\/s1470-2045(10)70070-x.","journal-title":"Lancet Oncol."},{"issue":"21","key":"18532_CR26","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1056\/nejmoa022343","volume":"347","author":"JBF Hulscher","year":"2002","unstructured":"Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662\u20139. https:\/\/doi.org\/10.1056\/nejmoa022343.","journal-title":"N Engl J Med."},{"issue":"6","key":"18532_CR27","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1097\/sla.0b013e31815c4037","volume":"246","author":"JMT Omloo","year":"2007","unstructured":"Omloo JMT, Lagarde SM, Hulscher JBF, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid\/distal esophagus. Ann Surg. 2007;246(6):992\u20131001. https:\/\/doi.org\/10.1097\/sla.0b013e31815c4037.","journal-title":"Ann Surg."},{"issue":"2","key":"18532_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/bjs.9345","volume":"101","author":"M Degiuli","year":"2014","unstructured":"Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101(2):23\u201331. https:\/\/doi.org\/10.1002\/bjs.9345.","journal-title":"Br J Surg."},{"issue":"5","key":"18532_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/nejmoa0707035","volume":"359","author":"M Sasako","year":"2008","unstructured":"Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453\u201362. https:\/\/doi.org\/10.1056\/nejmoa0707035.","journal-title":"N Engl J Med."},{"issue":"2","key":"18532_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s10147-007-0727-1","volume":"13","author":"Y Yonemura","year":"2008","unstructured":"Yonemura Y, Wu CC, Fukushima N, et al. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol. 2008;13(2):132\u20137. https:\/\/doi.org\/10.1007\/s10147-007-0727-1.","journal-title":"Int J Clin Oncol."},{"issue":"1","key":"18532_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/bjs\/znac373","volume":"110","author":"Y Kurokawa","year":"2023","unstructured":"Kurokawa Y, Doki Y, Mizusawa J, et al. Five-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001). Br J Surg. 2023;110(1):50\u20136.","journal-title":"Br J Surg."},{"issue":"9007","key":"18532_CR32","first-page":"995","volume":"347","author":"A Cuschieri","year":"1996","unstructured":"Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Surg Cooperat Group. 1996;347(9007):995\u20139.","journal-title":"Surg Cooperat Group."},{"issue":"9\u201310","key":"18532_CR33","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/sj.bjc.6690243","volume":"79","author":"A Cuschieri","year":"1999","unstructured":"Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79(9\u201310):1522\u201330. https:\/\/doi.org\/10.1038\/sj.bjc.6690243.","journal-title":"Br J Cancer."},{"issue":"16","key":"18532_CR34","doi-asserted-by":"publisher","first-page":"904","DOI":"10.21037\/atm-22-3810","volume":"10","author":"YS Mao","year":"2022","unstructured":"Mao YS, Gao SG, Li Y, et al. Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501). Ann Transl Med. 2022;10(16):904\u2013904. https:\/\/doi.org\/10.21037\/atm-22-3810.","journal-title":"Ann Transl Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18532-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:33:26Z","timestamp":1767573206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18532-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["18532"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18532-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}